Home
Immune Checkpoint Proteins

Immune Checkpoint Proteins

Bio X Cell offers a comprehensive portfolio of immune checkpoint blockade antibodies, including well-characterized clones targeting PD-1, CTLA-4, PD-L1, LAG-3, TIGIT, and more. These antibodies are validated for effectively inhibiting checkpoint pathways and are trusted tools for advancing immuno-oncology research.

Immune checkpoint proteins act as guardians of self-tolerance, preventing overactivation of the immune system and minimizing collateral tissue damage. However, tumor cells exploit these pathways to suppress tumor-specific T cells and evade immune destruction. Blocking checkpoint ligand–receptor interactions with functional antibodies, increasingly with bispecific formats, remains one of the most promising strategies for cancer immunotherapy.

Bio X Cell antibodies are specifically formulated for sensitive checkpoint studies in vivo and translational models. Each antibody is ultrapure (≥95% purity), with endotoxin levels as low as ≤0.5 EU/mg, and completely free from preservatives and stabilizers, ensuring consistent performance across in vivo and in vitro organoid or organ-on-chip workflows.

Antibodies Targeting PD-1: Bio X Cell offers industry-leading in vivo-ready antibodies against PD-1, a critical checkpoint receptor on T cells, including PD-1 bispecific antibodies designed to simultaneously engage PD-1 and a secondary target, enabling dual checkpoint modulation and other novel research opportunities in tumor immunology.
Antibodies Targeting PD-L1: PD-L1 expression on tumor cells and antigen-presenting cells plays a major role in immune evasion. Bio X Cell PD-L1 antibodies are industry leading, in vivo-ready, and are validated for blocking PD-1/PD-L1 interactions, restoring T-cell activity, and enabling reproducible preclinical studies.
Antibodies Targeting CTLA-4: CTLA-4 regulates early T-cell activation and is a cornerstone checkpoint in cancer immunotherapy. Bio X Cell CTLA-4 antibodies deliver high sensitivity and reproducibility, making them essential for studies in T-cell regulation and combination checkpoint blockade in vivo and in in vitro organoid studies.
Antibodies Targeting Emerging Checkpoints (LAG-3, TIGIT, and more): Next-generation checkpoint targets, including LAG-3 and TIGIT, are key players in immune regulation and cancer progression. Bio X Cell offers antibodies against these emerging targets, enabling researchers to evaluate novel checkpoint blockade strategies in preclinical models.